At its June 29, 2026 annual meeting, Kairos Pharma Ltd. stockholders approved an amendment to the certificate of incorporation to allow a reverse stock split with a ratio between 1:3 and 1:250, to be determined by the Board of Directors. Stockholders also approved increasing the 2023 Equity Incentive Plan by 5,000,000 shares of common stock and adding an evergreen provision for a 5% annual increase in available shares for ten years. Additionally, the company elected four directors, ratified Weinberg & Company, P.A. as independent auditors, and approved executive compensation on an advisory basis. The company operates in the pharmaceutical industry and develops medical treatments.
